Assessing the prognostic value of PAX2 and PTEN in endometrial carcinogenesis

in Endocrine-Related Cancer
Restricted access

In order to avoid the consequences of over- and under-treatment of endometrial hyperplasia, diagnostic accuracy and progression risk assessment must be improved. The aim of this study was to assess whether PAX2 or PTEN expression could predict progression-free survival in endometrial intraepithelial neoplasia (EIN) and endometrial endometrioid carcinoma (EEC). Immunohistochemistry for detection of PAX2 and PTEN was performed on 348 endometrial samples; 75 proliferative endometrium (PE), 36 EIN and 237 EEC. Cases classified as PTEN null (1 or more glands negatively stained) were more prevalent in EEC than in PE and EIN (64% EEC vs 11% PE/EIN). A progressive decrease in PAX2 expression was observed from PE to EIN to EEC. Long-term clinical follow-up (6–310 months, median: 126) was available for 62 PE cases, all 36 EIN cases and 178 EEC cases. No patients with PE demonstrated progression to EIN or EEC. Progression of disease was observed in 10 (28%) EIN patients. These patients had significantly lower PAX2 expression than those that regressed (P = 0.005). Progression-free survival analysis revealed that EIN patients with a high-risk PAX2 expression score (H-score ≤75) had a higher probability of progression of disease in comparison to those with a low-risk score (H-score >75). PAX2 expression was not prognostic in EEC nor was PTEN status of prognostic value in either EIN or EEC. PAX2 expression analysis by means of H-score has prognostic potential for the identification of high-risk progression cases in EIN but needs to be validated in a larger cohort.


      Society for Endocrinology

Article Information


All Time Past Year Past 30 Days
Abstract Views 225 225 107
Full Text Views 1133 1133 8
PDF Downloads 90 90 6


Related Articles


  • View in gallery

    Example of an EIN lesion immunostained for the detection of (A and B) PAX2 or (C and D) PTEN protein. The D-score was −0.5. (A) Intensity of PAX2 staining was observed to vary across the lesion. Of note, glands with weak expression and glands with strong expression tended to group within the lesion. (B) A close-up of glands indicated by the box in (A) compares a gland with low expression (top) with a gland with high PAX2 expression (bottom). PAX2 expression could also vary within a single gland with some nuclei strongly expressing PAX2 neighbouring nuclei that did not. (C) This lesion was defined as PTEN-null due to the presence of one or more PTEN-null glands (null glands indicated by absence of PTEN staining). PTEN-negative staining was very distinct from PTEN-positive staining with neighbouring glands showing contrasting expression in some areas. (D) A close-up of the glands indicated by the box in (C) emphasising that PTEN staining was very distinct readily distinguishing PTEN-positive (bottom) glands from PTEN-negative glands (top). Scale bar represents 100 µm. A full colour version of this figure is available at

  • View in gallery

    PAX2 expression according to diagnosis. All diagnostic categories had significantly different PAX2 expression scores (one-way ANOVA, P < 0.05).

  • View in gallery

    PAX2 expression of EIN patients that demonstrated either progression (n = 10) or regression (n = 26) in the follow-up. Patients with an initial EIN diagnosis where progression was observed in the follow-up had a significantly lower PAX2 expression score than those that regressed (independent samples t-test, P = 0.005).

  • View in gallery

    Long-term progression-free survival curve of patients initially diagnosed with EIN according to risk status determined by PAX2 expression score. For EIN samples that were defined as high-risk, where PAX2 ≤75 (n = 11, red) patients had a significantly lower progression-free survival than low-risk patients, where PAX >75 (n = 25, blue) (Kaplan–Meier log rank, P = 0.001). A full colour version of this figure is available at


Akiyama-AbeAMinaguchiTNakamuraYMichikamiHShikamaANakaoSSakuraiMOchiHOnukiMMatsumotoKet al. 2013 Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas. British Journal of Cancer 109 17031710. (

AllisonKHUpsonKReedSDJordanCDNewtonKMDohertyJSwisherEMGarciaRL 2012 PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia. International Journal of Gynecological Pathology 31 151159. (

BaakJPAØrboAVan DiestPJJiwaMde BruinPBroeckaertMSnijdersWBoodtPJFonsGBurgerCet al. 2001 Prospective multicenter evaluation of the mophometric D-score for prediction of the outcome of endometrial hyperplasias. American Journal of Surgical Pathology 25 930935.

BaakJPMutterGLRobboySvan DiestPJUyterlindeAMØrboAPalazzoJFianneBLøvslettKBurgerCet al. 2005a The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization Classification System. Cancer 103 23042312. (

BaakJPAvan DiermenBSteinbakkAJanssenESkalandIMutterGLFianeBLøvslettK 2005b Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Human Pathology 36 555561. (

BergeronCNogalesFFMasseroliMAbelerVDuvillardPMüller-HolznerEPickartzHWellsM 1999 A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. American Journal of Surgical Pathology 23 11021108. (

BokhmanJV 1983 Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology 15 1017. (

DaniilidouKFrangou-PlemenouMGrammatikakisJGrigoriouOVitoratosNKondi-PafitiA 2013 Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study. Journal of the Balkan Union of Oncology 18 195201.

FengZ-ZChenJ-WYangZ-RLuG-ZCaiZ-G 2012 Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression. Medical Oncology 29 304310. (

HechtJLInceTABaakJPBakerHEOgdenMWMutterGL 2005 Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Modern Pathology 18 324330. (

JoinerAKQuickCMJeffusSK 2015 PAX2 expression in simultaneously diagnosed WHO and EIN classification systems. International Journal of Gynecological Pathology 34 4046. (

KahramanKKiremitciSTaskinSKankayaDSertcelikAOrtacF 2012 Expression pattern of PAX2 in hyperplastic and malignant endometrium. Archives of Gynecology and Obstetrics 286 173178. (

KanamoriYKigawaJItamochiHSultanaHSuzukiMOhwadaMKamuraTSugiyamaTKikuchiYKitaT 2002 PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. International Journal of Cancer 100 686689. (

KendallBSRonnettBMIsacsonCChoKRHedrickLDiener-WestMKurmanRJ 1998 Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. American Journal of Surgical Pathology 22 10121019.

KurmanRJCarcangiuMLHerringtonCS & YoungRH 2014 WHO Classification of Tumours of Female Reproductive Organs. Lyon, France: International Agency for Research on Cancer.

KuroseKZhouX-PArakiTCannistraSAMaherEREngC 2001 Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. American Journal of Pathology 158 20972106. (

LaceyJVMutterGLRonnettBMIoffeOBDugganMARushBBGlassAGRichessonDAChatterjeeNLangholzBet al. 2008 PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Research 68 60146020. (

LeeHChoiHJKangCSLeeHJLeeWSParkCS 2012 Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Modern Pathology 25 15081515. (

MackayHJGallingerSTsaoMSMcLachlinCMTuDKeiserKEisenhauerEAOzaAM 2010 Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). European Journal of Cancer 46 13651373. (

MonteNMWebsterKANeubergDDresslerGRMutterGL 2010 Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Research 70 62256232. (

MutterGL & Group TIENW 2000 Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? Gynecologic Oncology 76 287290. (

MutterGLLinM-CFitzgeraldJTKumJBBaakJLeesJAWengL-PEngC 2000 Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. Journal of the National Cancer Institute 92 924930. (

MutterGLInceTABaakJPKustGAZhouX-PEngC 2001 Molecular identification of latent precancers in histologically normal endometrium. Cancer Research 61 43114314.

ØrboAArnesMLysåLMStraumeB 2015 Expression of PAX2 and PTEN correlates to therapy response in endometrial hyperplasia. Anticancer Research 35 64016409.

PavlakisKMessiniIVrekoussisTPanoskaltsisTChrissanthakisDYiannouPStathopoulosEN 2010 PTEN-loss and nuclear atypia of EIN in endometrial biopsies can predict the existence of a concurrent endometrial carcinoma. Gynecologic Oncology 119 516519. (

QuickCMLauryARMonteNMMutterGL 2012 Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia. American Journal of Clinical Pathology 138 678684. (

ShangY 2007 Hormones and cancer. Cell Research 17 277. (

SkovBBroholmHEngelUFranzmannM-BNielsenALauritzenASkovT 1997 Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. International Journal of Gynecological Pathology 16 3337. (

SteinbakkASkalandIGudlaugssonEJanssenEAKjellevoldKHKlosJLøvslettKFianeBBaakJP 2009 The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer. American Journal of Obstetrics and Gynecology 200 78.e7178.e78. (

StrisselPLEllmannSLoprichEThielFFaschingPAStieglerEHartmannABeckmannMWStrickR 2008 Early aberrant insulin‐like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen. International Journal of Cancer 123 28712879. (

UegakiKKanamoriYKigawaJKawaguchiWKanekoRNaniwaJTakahashiMShimadaMOishiTItamochiHet al. 2005 PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncology Reports 14 389392.

UpsonKAllisonKHReedSDJordanCDNewtonKMSwisherEMDohertyJAGarciaRL 2012 Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. American Journal of Obstetrics and Gynecology 207 36.e3136.e38. (

UsubutunAMutterGLSaglamADolgunAOzkanEAInceTAkyolABulbulHDCalayZErenFet al. 2012 Reproducibility of endometrial intraepithelial neoplasia diagnosis is good, but influenced by the diagnostic style of pathologists. Modern Pathology 25 877884. (

WuHChenYLiangJShiBWuGZhangYWangDLiRYiXZhangH 2005 Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438 981987. (

YangHPMeekerAGuidoRGunterMJHuangGSLuhnPd’AmbrosioLWentzensenNShermanME 2015 PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes and Control 26 17291736. (


Google Scholar